Results of a long-term (6-month) pooled analysis including patients with unresolved symptoms of generalized anxiety disorder5
*P<0.001 EFFEXOR XR vs. placebo.
†P<0.01 EFFEXOR XR vs. placebo.
Trial population (intent-to-treat): 767.
Remission
was defined as HAM-A ≤7.
Last-observation-carried-forward (LOCF) analysis.
Pooled data from 2 multicenter, randomized, double-blind, parallel-group, placebo-controlled trials
in outpatients meeting DSM-IV® criteria for GAD. Study A had a flexible-dose regimen, with all patients in the EFFEXOR XR treated group receiving 75 to 225 mg/day. After titration, the mean daily dose for EFFEXOR XR was between 143 and 176 mg. The EFFEXOR XR group was significantly better than placebo (P<0.001) based on primary efficacy measures. Study B had a fixed-dose regimen without titration: placebo and EFFEXOR XR 37.5, 75, and 150 mg/day. EFFEXOR XR 37.5 and 150 mg/day (P<0.001) and 75 mg/day (P<0.05) were significantly better than placebo based on primary efficacy measures.
